Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Teva Pharmaceutical Industries has launched the generic equivalent to Xeloda (capecitabine) tablets, 150mg and 500mg, in the US.
Subscribe to our email newsletter
Genentech is currently marketing Xeloda in the US. Teva claims that it was the first to receive approval on its abbreviated new drug application from the US Food and Drug Administration on 16 September 2013 and is launching on 7 March 2014 per a settlement agreement.
Xeloda is used for the treatment of metastatic colorectal cancer and metastatic breast cancer.
Xeloda is used as a single medicine to treat metastatic colorectal cancer. In medical studies, people lived longer when they took other cancer medicines at the same time that they took 5-fluorouracil (5-FU) and leucovorin.
In medical studies, Xeloda used as a single medicine was no worse than 5-FU and leucovorin taken together. When compared to 5-FU and leucovorin, Xeloda did not improve survival.
For metastatic breast cancer, Xeloda is taken together with another medicine called docetaxel. Breast cancer that has spread to other parts of the body and has not improved after treatment with other medicines. These medicines include paclitaxel and anthracycline-containing medicine such as doxorubicin.